- Gene Therapy for Kids’ Deadly Muscle Disease Fails to Reach Trial Goal Yahoo Finance
- Sarepta’s Duchenne gene therapy fails to meet primary endpoint in pivotal trial STAT
- SRPT Stock Crashes To Six-Year Low As Its Gene Therapy Flops In Its Biggest Test Investor’s Business Daily
- Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy Business Wire
- Sarepta’s muscular dystrophy therapy fails to meet main goal in late-stage trial CNBC
- View Full Coverage on Google News
Read original article here